AR081259A1 - Metodo para la terapia del cancer - Google Patents
Metodo para la terapia del cancerInfo
- Publication number
- AR081259A1 AR081259A1 ARP110101831A ARP110101831A AR081259A1 AR 081259 A1 AR081259 A1 AR 081259A1 AR P110101831 A ARP110101831 A AR P110101831A AR P110101831 A ARP110101831 A AR P110101831A AR 081259 A1 AR081259 A1 AR 081259A1
- Authority
- AR
- Argentina
- Prior art keywords
- nuclear localization
- cancer
- increase
- commd1 protein
- peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
Un método para el tratamiento del cáncer mediante el incremento de la localización nuclear de la proteína COMMD1, lo cual se asocia con la disminución o bloqueo de la proliferación de la célula de cáncer. Uso de agentes que incrementan la localización nuclear de la proteína COMMD1 en la fabricación de un medicamento para la terapia del cáncer. Dichos agentes pueden ser péptidos o proteínas, entre otros compuestos. También se relaciona con la optimización de un péptido, proveniente de la secuencia HARIKPTFRRLKWKKYKGKFW, para incrementar la localización nuclear de la proteína COMMD1 y, de esa forma, aumentar el efecto antitumoral de dicho péptido. Reivindicación 14: Combinación farmacéutica para el tratamiento del cáncer que comprende uno o varios agentes que incrementan la localización nuclear de la proteína COMMD1, y uno o varios fármacos específicos para la quimioterapia estándar del cáncer. Reivindicación 15: La combinación farmacéutica de la reivindicación 14 donde el agente que incrementa la localización nuclear de la proteína COMMD1 comprende el péptido con la secuencia de aminoácidos identificada como SEQ ID Ns 3 y el fármaco específico para la quimioterapia estándar se selecciona entre cisplatino y 5-FU.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2010000113A CU23897B1 (es) | 2010-05-31 | 2010-05-31 | Péptido para la terapia del cáncer |
Publications (1)
Publication Number | Publication Date |
---|---|
AR081259A1 true AR081259A1 (es) | 2012-07-18 |
Family
ID=45067129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110101831A AR081259A1 (es) | 2010-05-31 | 2011-05-27 | Metodo para la terapia del cancer |
Country Status (16)
Country | Link |
---|---|
US (2) | US8729226B2 (es) |
EP (1) | EP2578227B1 (es) |
JP (1) | JP5827322B2 (es) |
KR (1) | KR101847170B1 (es) |
CN (1) | CN102917725B (es) |
AR (1) | AR081259A1 (es) |
AU (1) | AU2011260745B2 (es) |
BR (1) | BR112012030668B1 (es) |
CA (1) | CA2799066C (es) |
CU (1) | CU23897B1 (es) |
DK (1) | DK2578227T3 (es) |
MX (1) | MX2012013923A (es) |
RU (1) | RU2577993C2 (es) |
UA (1) | UA112522C2 (es) |
WO (1) | WO2011150897A2 (es) |
ZA (1) | ZA201208905B (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2105567C1 (ru) * | 1995-12-01 | 1998-02-27 | Сергей Юрьевич Родионов | Способ лечения злокачественных опухолей |
CU23582A1 (es) | 2006-02-24 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Péptidos con capacidad anti-tumoral e inmunomoduladora |
CU23674A1 (es) * | 2007-07-31 | 2011-05-27 | Ct Ingenieria Genetica Biotech | Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica |
-
2010
- 2010-05-31 CU CU2010000113A patent/CU23897B1/es active IP Right Grant
-
2011
- 2011-05-27 AR ARP110101831A patent/AR081259A1/es active IP Right Grant
- 2011-05-31 WO PCT/CU2011/000003 patent/WO2011150897A2/es active Application Filing
- 2011-05-31 RU RU2012157289/10A patent/RU2577993C2/ru active
- 2011-05-31 DK DK11728172.5T patent/DK2578227T3/en active
- 2011-05-31 CA CA2799066A patent/CA2799066C/en active Active
- 2011-05-31 EP EP11728172.5A patent/EP2578227B1/en active Active
- 2011-05-31 CN CN201180026853.7A patent/CN102917725B/zh active Active
- 2011-05-31 UA UAA201215130A patent/UA112522C2/uk unknown
- 2011-05-31 US US13/700,286 patent/US8729226B2/en active Active
- 2011-05-31 JP JP2013512751A patent/JP5827322B2/ja active Active
- 2011-05-31 KR KR1020127033777A patent/KR101847170B1/ko active IP Right Grant
- 2011-05-31 MX MX2012013923A patent/MX2012013923A/es active IP Right Grant
- 2011-05-31 AU AU2011260745A patent/AU2011260745B2/en active Active
- 2011-05-31 BR BR112012030668-5A patent/BR112012030668B1/pt active IP Right Grant
-
2012
- 2012-11-26 ZA ZA2012/08905A patent/ZA201208905B/en unknown
-
2013
- 2013-11-08 US US14/075,276 patent/US9145554B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2577993C2 (ru) | 2016-03-20 |
MX2012013923A (es) | 2013-01-24 |
CN102917725B (zh) | 2014-09-17 |
WO2011150897A3 (es) | 2012-03-15 |
AU2011260745B2 (en) | 2014-08-07 |
US20130224313A1 (en) | 2013-08-29 |
US20140206621A1 (en) | 2014-07-24 |
CU23897B1 (es) | 2013-05-31 |
DK2578227T3 (en) | 2017-03-27 |
CN102917725A (zh) | 2013-02-06 |
JP2013530162A (ja) | 2013-07-25 |
CU20100113A7 (es) | 2012-06-21 |
BR112012030668A2 (pt) | 2020-08-25 |
CA2799066A1 (en) | 2011-12-08 |
KR20130089167A (ko) | 2013-08-09 |
AU2011260745A1 (en) | 2012-12-06 |
BR112012030668B1 (pt) | 2022-03-29 |
RU2012157289A (ru) | 2014-07-20 |
EP2578227B1 (en) | 2016-12-28 |
EP2578227A2 (en) | 2013-04-10 |
JP5827322B2 (ja) | 2015-12-02 |
US8729226B2 (en) | 2014-05-20 |
WO2011150897A2 (es) | 2011-12-08 |
ZA201208905B (en) | 2013-07-31 |
UA112522C2 (uk) | 2016-09-26 |
KR101847170B1 (ko) | 2018-05-28 |
US9145554B2 (en) | 2015-09-29 |
CA2799066C (en) | 2019-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20140382A1 (es) | Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas | |
WO2014170389A8 (en) | Enhanced adoptive cell therapy | |
ES2691070T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
CL2012003745A1 (es) | Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
BR112014021101A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo | |
CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
PH12021551189A1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
ECSP13012978A (es) | Inhibidores de glucosilceramida sintasa | |
BR112013003823A2 (pt) | conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados | |
BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
PE20160244A1 (es) | Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos | |
CL2015002620A1 (es) | Derivados piridin-4-ilo | |
WO2011020089A3 (en) | Target genes for cancer therapy | |
MX2017011633A (es) | Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas. | |
WO2014151369A3 (en) | Stabilized ezh2 peptides | |
EA201491702A1 (ru) | Оптимизированные терапевтические агенты для подкожного введения | |
IN2014DN06920A (es) | ||
BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos | |
BR112015005443A2 (pt) | tratamento combinado com fármaco interferente de netrina-1 e fármaco quimioterápico | |
CL2015001849A1 (es) | Anticuerpos anti-lamp1 y conjugados anticuerpos fármaco, y usos de estos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |